Elderberry
What studies of elderberry found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, the randomised trial (very low certainty): 6 of 9 findings are C.
9 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Elderberry might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Elderberry · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Anxiety1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on anxiety in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Anxiety (number of subjects with symptom)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Cognition (brain fog)1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 1.45 (large).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Cognition (brain fog) improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on cognition (brain fog) in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
- Effect size 1.45 (large)
How big was the difference?
1.45, large. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Lack of concentration VAS (0-100)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Some concerns
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Fatigue1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 0.99 (large).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on fatigue in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
- Effect size 0.99 (large)
How big was the difference?
0.99, large. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Fatigue (severity)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Low mood or anxiety1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Low mood or anxiety improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on low mood or anxiety in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Altered mood (number of subjects with symptom)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Sleep1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Sleep improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on sleep in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Insomnia (number of subjects with symptom)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Autonomic symptoms1 study · 37 people took elderberry Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
No clear difference in autonomic symptoms.
The evidence is very uncertain about the effect of elderberry on autonomic symptoms in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Palpitation (number of subjects with symptom)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Breathlessness1 study · 37 people took elderberry Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
No clear difference in breathlessness.
The evidence is very uncertain about the effect of elderberry on breathlessness in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Dyspnea (number of subjects with symptom)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Pain1 study · 37 people took elderberry Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 74 people found no clear difference; a small benefit can't be ruled out.
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
No clear difference in pain.
The evidence is very uncertain about the effect of elderberry on pain in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 74 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Headache (number of subjects with symptom)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Daily life and health overall
Quality of life1 study · 37 people took elderberry Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (74 in all); effect size 0.58 (moderate).
The randomised trial74 randomised · 30 days · 1 Capsule (250 mg), twice daily
Quality of life improved more than in the comparison group.
The evidence is very uncertain about the effect of elderberry on quality of life in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (74 in all)
- Effect size 0.58 (moderate)
How big was the difference?
0.58, moderate. The effect size compares elderberry with group b i.e. conventional management (standard of care- vitamins like b complex, vitamin c, zinc supplements or medications as per symptom requirement.).
See the 1 study
-
- People in the study
- 74 randomised
- Dose
- 1 Capsule (250 mg), twice daily
- Outcome
- Physical Domain WHO-QOL BREF
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- Some concerns
- Missing outcome data
- Low
- Measurement of the outcome
- High
- Selection of the reported result
- Low
Side effects
Stopping because of side effects1 study
These wereresolved on their own and did not require any pause of study product or treatment
Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study (2022)
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
250 mg at the start
- 2Top dose
Most often 250 mg (1 of 1 studies)
Doses across 1 study
250 to 250 mg.
Each study’s dose, as printed
All papers
- Potential use of Immunodaat® (Botanical extract of Elderberry -Sambucus Nigra L.) in the management of Post Covid-19 symptoms- a comparative, multi-centric, randomized, clinical study2022 · randomised trial · 74 randomised · preprint